{"id":1443282,"date":"2026-01-14T07:34:22","date_gmt":"2026-01-14T06:34:22","guid":{"rendered":"https:\/\/www.payoff.ch\/news\/novo-nordisk-bottoming-out-with-room-for-improvement"},"modified":"2026-01-15T08:56:11","modified_gmt":"2026-01-15T07:56:11","slug":"novo-nordisk-bottoming-out-with-room-for-improvement","status":"publish","type":"post","link":"https:\/\/www.payoff.ch\/en\/news\/novo-nordisk-bottoming-out-with-room-for-improvement","title":{"rendered":"Novo Nordisk: bottoming out with room for improvement"},"content":{"rendered":"\n

The Danish pharmaceutical company Novo Nordisk<\/a><\/strong> made headlines at the beginning of the year: The company is now also selling its popular weight loss drug Wegovy via Amazon. To be more precise, Amazon Pharmacy is now offering the newly approved tablet in the USA. Insured customers can obtain a monthly ration for USD 25, while self-pay customers have to fork out around USD 149 per month. The pills will even be available in Amazon Pharmacy kiosks in the coming weeks. The US Food and Drug Administration (FDA) only approved the pill in December. The deal opens up a new distribution channel for Novo Nordisk: Wegovy will now be widely available online in addition to traditional pharmacies.<\/p>\n\n\n\n

The Danes are hoping that the more convenient form of administration and wide availability will give the weight loss drug a new boost. This is urgently needed, as the company had to issue several profit warnings last year, which also put the share under pressure. The Wegovy pill is now seen as an important building block to get the business back on track after the slump. Accordingly, Novo is also investing heavily: billions have recently been invested in the expansion of production capacities for GLP-1 drugs alone in order to eliminate supply bottlenecks and meet the enormous demand. <\/p>\n\n\n\n

GLP-1 market: boom, competition and price war<\/h3>\n\n\n\n

The market for GLP-1-based drugs for the treatment of obesity and diabetes is experiencing an unprecedented boom. Semaglutide, the active ingredient in Wegovy, was the pioneer in this class and at times made Novo Nordisk the most valuable company in Europe. However, competition is now fiercer. First and foremost the US competitor Eli Lilly<\/a><\/strong> is forcing its way onto the market with its drug Mounjaro and is enjoying impressive success. Novo Nordisk is feeling the headwind: “Lilly is clearly ahead at the moment,” commented Jefferies analyst Michael Leuchten after the latest quarterly figures. In fact, Lilly has recently presented much stronger results and raised its forecasts, while Novo has fallen behind.<\/p>\n\n\n\n

In addition, there is price pressure from more and more suppliers, especially in China. The country could develop into one of the largest obesity markets in the world. According to experts, more than 65% of the 1.4 billion Chinese population are at risk of being overweight or obese by 2030. Local manufacturers such as CSPC and Hangzhou Jiuyuan are positioning their own GLP-1 preparations and forcing Novo to go on a price offensive: in some Chinese provinces, the list prices of the two highest Wegovy dosages were recently reduced by 48%. China is not the only market with falling GLP-1 prices. In India, Novo Nordisk already reduced Wegovy prices by up to 37% in November in order to reach more patients in this emerging market. And in the USA – currently the most lucrative market – manufacturers are also showing a willingness to compromise: both Novo Nordisk and Eli Lilly reached agreements in November to significantly reduce the prices of their sales drugs. <\/p>\n\n\n\n

Outlook: What will February 4 bring?<\/h3>\n\n\n\n

On February 4, Novo Nordisk will open its books and present its 2025 financial statements. However, observers expect a rather cautious tone from management. In view of the ongoing pressure from Eli Lilly and the upcoming patent expiries, such as semaglutide in China, forecasts are likely to fall. Carlsquare analysts point out that the growth prospects for 2026 are bleak due to competition in the diabetes market and expiring intellectual property rights, which means that Novo Nordisk could also give a conservative outlook. Nevertheless, the Group has a robust pipeline of new drugs that are set to be launched on the market in the coming years. Among these, the aforementioned Wegovy pill, which was approved in the USA at the end of 2025, stands out in particular. As the world’s first oral GLP-1 pill for obesity, it gives Novo Nordisk a head start in a segment that is still largely unoccupied. According to company projections, oral forms could account for over a third of the GLP-1 market by 2030 – an enormous additional sales potential. <\/p>\n\n\n\n

After plummeting in 2025, the Novo Nordisk share has recently bottomed out and is now gradually picking up again. Since its interim low in late fall, it has already made significant gains. In chart terms, the downward trend has therefore been halted for the time being. Nevertheless, Novo Nordisk is still lagging behind Eli Lilly on the stock market. Lilly’s share price has hovered close to its all-time high over the past two years, while Novo has lost a large part of its previous stock market value. <\/p>\n\n\n\n

Investment solutions<\/strong><\/h3>\n\n\n\n

Investors who would like to bet on the Novo Nordisk share continuing its recovery can invest in the mini-future long MNOIXT<\/a><\/strong> from Leonteq on the long side. The product offers a multiplier of 5.2 and thus benefits disproportionately from rising prices of the underlying. The knock-out is located at DKK 324.7948 and is 14.3% away from the current price level.<\/p>\n\n\n\n

Anyone assuming that the pharmaceuticals share will take a breather after the dynamic turnaround can buy the Barrier Reverse Convertible RNOAGV<\/a><\/strong> from Bank Vontobel with a remaining term until October 2026. The product offers the prospect of a return of 5.55% p.a., with a barrier of DKK 204.51 – a solid 46% buffer.<\/p>\n\n\n\n

More return is possible with a BRC if you add competitor Eli Lilly to the mix. The multi-product issued by Leonteq AENOTQ<\/a><\/strong> issued by Leonteq promises a potential return of 11.50% p.a., with an equally high risk buffer. Worst performer Novo Nordisk is currently 45% away from the barrier. The maximum term extends until April 7, 2027, but the callable function means that redemption may occur before then. Leonteq has the option of early redemption every three months.<\/p>\n\n\n\n

\"\"<\/figure>\n\n\n\n
\"\"<\/figure>\n\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

The outlook for the Danish GLP1 specialist has brightened recently. In addition, there is a promising technical turnaround on the chart – which makes the pharmaceutical stock doubly interesting. <\/p>\n","protected":false},"author":7,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"ngg_post_thumbnail":0,"footnotes":""},"categories":[222],"tags":[],"class_list":["post-1443282","post","type-post","status-publish","format-standard","hentry","category-trading-desk-en"],"acf":[],"_links":{"self":[{"href":"https:\/\/www.payoff.ch\/en\/wp-json\/wp\/v2\/posts\/1443282","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.payoff.ch\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.payoff.ch\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.payoff.ch\/en\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/www.payoff.ch\/en\/wp-json\/wp\/v2\/comments?post=1443282"}],"version-history":[{"count":3,"href":"https:\/\/www.payoff.ch\/en\/wp-json\/wp\/v2\/posts\/1443282\/revisions"}],"predecessor-version":[{"id":1443286,"href":"https:\/\/www.payoff.ch\/en\/wp-json\/wp\/v2\/posts\/1443282\/revisions\/1443286"}],"wp:attachment":[{"href":"https:\/\/www.payoff.ch\/en\/wp-json\/wp\/v2\/media?parent=1443282"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.payoff.ch\/en\/wp-json\/wp\/v2\/categories?post=1443282"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.payoff.ch\/en\/wp-json\/wp\/v2\/tags?post=1443282"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}